; or (ii) to meet the requirements to receive premarket approval under section 587B or a technology certification order under section 587D, as applicable. (b) Accreditation (1) Accreditation Program (A) In general The Secretary may provide for accreditation under this section through programs administered by the Food and Drug Administration, by other non-Federal government agencies, or by qualified nongovernmental organizations. A person may be accredited for the review of both applications submitted under sections 587B and 587D as described in subsection (a)(1)(A) and to conduct inspection activities under subsection (a)(2)(A), or for a subset of such review or activities. (B) Eligible persons Not later than 180 days after the date of enactment of the Verifying Accurate Leading-edge IVCT Development Act of 2020 , the Secretary shall issue draft guidance on the criteria that the Secretary will use to accredit or deny accreditation to a person who requests such accreditation under subsection (a), and not later than one year after the close of the comment period for the draft guidance issued in this section, issue final guidance. (C) Requirements (i) In general The Secretary shall not accredit or maintain accreditation for a person unless such person meets the minimum qualifications required under subsection (c). (ii) Scope of accreditation The accreditation of a person under this section shall specify the particular activities under subsection (a) for which such person is accredited. (D) Public list The Secretary shall publish on the internet website of the Food and Drug Administration a list of persons who are accredited under this section. Such list shall be updated on at least a monthly basis. The list shall specify the particular activity or activities under this section for which the person is accredited. (2) Accreditation Process (A) Accreditation process guidance The Secretary shall— (i) not later than 180 days after the date of enactment of the Verifying Accurate Leading-edge IVCT Development Act of 2020 ,